Lung cancer pill drastically cuts risk of death after surgery

May 15, 2023
8
1
35
Hallo!: A very interesting and promising new drug for NSCLC, in the quite old EGFR agents class, however, discussing a new drug under its Propietary Name Tagrisso in a non-medical forum, and not by its INN Osimertinib, is not acceptable, could be considered advertising against FDA; EMEA and other drug agencies policies, also citation of INN is of dubious morality.
Please delete this commercial brand from article.
Blessings +